Outlook Therapeutics, Inc. (OTLK) Phase 3 Data Supports Approval - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Outlook Therapeutics Incs. (OTLK) PT Raised to $8 at Brookline Capital Markets, Following Clinical Business Update
August 3, 2021 11:28 AM EDTBrookline Capital Markets analyst Kumaraguru Raja raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $8.00 (from $5.00) while maintaining a Buy rating.
Analyst comments: "A new biologics license application (BLA) submission, under the PHSA 351(a) regulatory pathway, for wet AMD is... More
Outlook Therapeutics Incs. (OTLK) PT Raised to $6 at H.C. Wainwright
August 3, 2021 10:56 AM EDTH.C. Wainwright analyst Douglas Tsao raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $6.00 (from $5.00) while maintaining a Buy rating.
... MorePre-Open Stock Movers 08/03: (OTLK) (TBIO) (HOLI) Higher; (CLX) (RNA) (KOPN) Lower (more...)
August 3, 2021 9:22 AM EDTPre-Open Stock Movers:
Outlook Therapeutics, Inc. (Nasdaq: OTLK) 34.5% HIGHER; announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 / LYTENAVA (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). Outlook Therapeutics will host a conference call and webcast today, August 3, 2021, at 8:00 a.m. ET (details below) to discuss the results of the study.
Translate Bio (NASDAQ: TBIO) 29.2% HIGHER; As part of Sanofis endeavor to... More
Outlook Therapeutics (OTLK) Climbs 41%
August 3, 2021 7:43 AM EDTOutlook Therapeutics (NASDAQ: OTLK) Climbs 41%
Earlier Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010... MoreOutlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010
August 3, 2021 6:03 AM EDTOutlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 / LYTENAVA (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). Outlook Therapeutics will host a... More
